Industries > Pharma > Biopharmaceuticals Contract Manufacturing Market Report 2022-2032

Biopharmaceuticals Contract Manufacturing Market Report 2022-2032

Forecasts by Source (Mammalian, Non-mammalian), by Service (Process Development (Downstream, Upstream), Fill & Finish Operations, Analytical & QC Studies, Packaging), by Product (Biologics (Monoclonal Antibodies (MABs), Recombinant Proteins, Vaccines, Antisense, RNAi, & Molecular Therapy, Others), Biosimilars), by Company Size (Small, Mid-sized, Large), by Scale of Operations (Preclinical, Clinical, Commercial) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery

PUBLISHED: 26 January 2022
PAGES: 659
PRODUCT CODE: PHA1162
SUBMARKET: Contract Services

WOOCS 2.2.1
DOWNLOAD FREE SAMPLE
SKU: PHA1162 Categories: , Tags: , , , , ,

Biopharmaceuticals Contract Manufacturing Market, 2022 to 2032- our new study reveals the latest industry trends, R&D progress, and predicted revenues

The U.S. is the Global Leader in Biopharmaceutical Business
The United States has been dubbed the “life sciences innovation capital” of the world, and it is a significant biopharmaceutical investor. The increased demand for biologics is likely to boost the expansion of the US biopharmaceuticals industry.

In terms of economic contributions and overall impacts, the biopharmaceutical sector in the United States is not only a worldwide leader in the development of innovative medicines, vaccines, and diagnostics, but it is also a highly valued industry. With a diverse employment base and vast research, manufacturing, and distribution infrastructure, the biopharmaceutical business in the United States is a major and innovative component of the country’s economy, with considerable influence on economies around the country.

There is a vast innovation ecosystem in the biopharmaceutical industry that drives and maintains this success. An extensive network of collaborators supports the discovery, development, and delivery of new medicines to patients through this innovation ecosystem, which is led by both small and large R&D-intensive companies. This network includes but is not limited to venture and other forms of private capital; health care providers; public and private sector researchers including academic medical researchers and private research institutes; and various other sectors. A strong biopharmaceutical innovation ecosystem and innovation-based policy make the United States the world leader in biopharmaceutical innovation. All these factors are anticipated to fuel the biopharmaceutical contract manufacturing market in the United States.

COVID-19 pandemic has brought India’s Biopharmaceuticals Sector into the Limelight
The Indian biotechnology industry has entered a new phase of growth, with the rest of the world increasingly appreciating the sector’s enormous potential to touch and improve people’s lives. In the middle of the pandemic, the successful production of contingent commodities like the Covid-19 vaccine and indigenous diagnostic kits in such a brief period has been a wonderful benefit to humanity. The Biotechnology Industry Research and Development Corporation (BIRAC) and the Department of Biotechnology (DBT) have been at the forefront of enhancing the country’s creative talents and potential.

The development of alternative Covid 19 solutions has been hastened by the Government of India’s Mission program COVID Suraksha and the Covid-19 Research Consortium, which is led by DBT and BIRAC. With significant contributions from different states, the nation is on its way to becoming a globally renowned Innovation Hub and Biomanufacturing Hub. Official Biotech policies are in existence or being developed in several states. It is the responsibility of the Department of Biotechnology’s Make In India (MII) Facilitation Cell, based at BIRAC alongside Invest India, to interact with States and assist them in formulating biotech policies, promote direct foreign investment, and improve the manufacturing sector, among other things.

What are the Market Driversw
• Rise in Investment by CMOs for Capacity Expansion
• Commercial success of biopharmaceuticals and consequent increase in demand for biopharmaceuticals
• Notable growth of biologics
• Robust biopharmaceuticals pipeline
• Cost and time-saving benefits offered by contract services
• Outsourcing as a Driver for Market Growth
• Growing Investments in Orphan Drugs

What are the Market Opportunities?
• Expansion of Fill and Finish CMOs
• Funding & investments
• Emerging Economies to Offer Lucrative Growth Opportunities
• Emergence of Single-Use Bioprocessing Equipment & Solutions

Discover how to stay ahead
Our 650+ page report provides 700+ tables and charts/graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at the overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing Biopharmaceuticals Contract Manufacturing Market. See how to exploit the opportunities.

Forecasts to 2032 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints, and challenges), PEST Analysis, Porter’s Five Forces, SWOT Analysis, product profiles, and commercial developments.

Discover sales predictions for the world market and sub-markets

Source
• Mammalian
• Non-mammalian

Service
• Process Development
– Downstream
– Upstream
• Fill & Finish Operations
• Analytical & QC studies
• Packaging

Product
• Biologics
– Monoclonal antibodies (MABs)
– Recombinant Proteins
– Vaccines
– Others
• Biosimilars

Company Size
• Small
• Mid-sized
• Large

Scale of Operations
• Preclinical
• Clinical
• Commercial

Region
• North America
• Europe
• Asia Pacific
• Latin America
• MEA

CTA

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for 5 regional and 17 leading national markets:

By Region

North America
• U.S.
• Canada

Europe
• Germany
• France
• UK
• Italy
• Spain
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• Southeast Asia
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America

Middle East & Africa
• GCC
• South Africa
• Rest of Middle East & Africa

Biopharmaceuticals Contract Manufacturing Market Report 2022-2032
Need industry data? Please contact us today.

Leading companies and the potential for market growth
Overall world revenue for Biopharmaceuticals Contract Manufacturing Market will surpass US$xx billion in 2022, our work calculates. We predict strong revenue growth through 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How the Biopharmaceuticals Contract Manufacturing Market report helps you
In summary, our 650+ page report provides you with the following knowledge:

• Revenue forecasts to 2032 for Biopharmaceuticals Contract Manufacturing Market, with forecasts for 5 segmentations of the biopharmaceuticals contract manufacturing market, with forecasts for 2 Sources, 4 Services, 2 Products, 2 Company Size, and 3 Scale of Operations sub-segments each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues

• Revenue forecasts to 2032 for 5 regional and 17 key national markets– See forecasts for the Biopharmaceuticals Contract Manufacturing market in North America, Europe, Asia Pacific, and Rest of the World. These regional markets have been further bifurcated by countries including the US, Canada, Brazil, Mexico, Germany, France, UK, Italy, Spain, China, India, Japan, Australia, South Korea, among other prominent economies.

• Prospects for established firms and those seeking to enter the market– including company profiles for 18 of the companies involved in the Biopharmaceuticals Contract Manufacturing Market. Some of the companies profiled in this report include AbbVie, Inc., AGC Biologics, Avantor, Binex Co., Ltd., Boehringer Ingelheim GmbH, Cambrex Corporation, Curia Global, Inc., FUJIFILM Diosynth Biotechnologies U.S.A., Inc., JRS PHARMA, Jubilant Pharma Limited, Lonza, Pfizer CentreOne, ProBioGen, Rentschler Biopharma SE, Samsung Biologics, Sandoz, TOYOBO CO., LTD., Thermo Fisher Scientific, and WuXi Biologics, among other prominent players.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Biopharmaceuticals Contract Manufacturing Market and leading companies. You will find data, trends, and predictions.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Biopharmaceuticals Contract Manufacturing Market Report 2022-2032: Forecasts by Source (Mammalian, Non-mammalian), by Service (Process Development (Downstream, Upstream), Fill & Finish Operations, Analytical & QC Studies, Packaging), by Product (Biologics (Monoclonal Antibodies (MABs), Recombinant Proteins, Vaccines, Antisense, RNAi, & Molecular Therapy, Others), Biosimilars), by Company Size (Small, Mid-sized, Large), by Scale of Operations (Preclinical, Clinical, Commercial) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Biopharmaceuticals Contract Manufacturing Market Report 2022-2032


Download sample pages

Complete the form below to download your free sample pages for Biopharmaceuticals Contract Manufacturing Market Report 2022-2032


Latest Pharma news

Visiongain Publishes Pharma Wholesale and Distribution Market Report 2022-2032

The pharma wholesale and distribution market was valued at US$511.80 billion in 2021 and is projected to grow at a CAGR of 7.84% during the forecast period 2022-2032.

29 September 2022

READ

Visiongain Publishes Mesenchymal Stem Cells Market Report 2022-2032

The mesenchymal stem cells market was valued at US$2.44 billion in 2021 and is projected to grow at a CAGR of 13.82% during the forecast period 2022-2032.

21 September 2022

READ

Visiongain Publishes Advanced Wound Care Management Market Report 2022-2032

The global advanced wound care management market is estimated to be valued at US$12,581.3 million in 2022. The market is projected to reach a market value of US$23,307.5 million by 2032 and is projected to grow at a CAGR of 6.36% during the forecast period 2022-2032.

16 September 2022

READ

Visiongain Publishes Gene Therapy R&D Market Report 2022-2032

The gene therapy R&D market was valued at US$1,653.0 million in 2021 and is projected to grow at a CAGR of 30.1% during the forecast period 2022-2032.

15 September 2022

READ